In yesterday’s Wall Street session, Landos Biopharma Inc. (NASDAQ:LABP) shares traded at $0.38, up 22.50% from the previous session.
As of this writing, 4 analysts cover Landos Biopharma Inc. (NASDAQ:LABP). The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $0.10, we find $1.05. Given the previous closing price of $0.31, this indicates a potential upside of 238.71 percent. LABP stock price is now -7.48% away from the 50-day moving average and -36.48% away from the 200-day moving average. The market capitalization of the company currently stands at $15.50M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
There are 3 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $1.05 as their price target over the next twelve months.
With the price target reduced from $30 to $1.40, Jefferies Downgraded its rating from Buy to Hold for Landos Biopharma Inc. (NASDAQ: LABP). On November 16, 2021, SVB Leerink Downgraded its previous ‘Outperform’ rating to ‘Mkt Perform’ on the stock reducing its target price from $20 to quote $16, while ‘Craig Hallum’ rates the stock as ‘Buy’.
In other news, RTW INVESTMENTS, LP, 10% Owner sold 300,000 shares of the company’s stock on Sep 23. The stock was sold for $207,000 at an average price of $0.69. Upon completion of the transaction, the 10% Owner now directly owns 3,975,722 shares in the company, valued at $1.51 million. Insiders disposed of 800,000 shares of company stock worth roughly $0.3 million over the past 1 year. A total of 22.86% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LABP stock. A new stake in Landos Biopharma Inc. shares was purchased by HRT FINANCIAL LP during the first quarter worth $20,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $8,000 in shares of LABP during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in Landos Biopharma Inc. valued at approximately $6,000. In total, there are 42 active investors with 58.40% ownership of the company’s stock.
Wednesday morning saw Landos Biopharma Inc. (NASDAQ: LABP) opened at $0.3009. During the past 12 months, Landos Biopharma Inc. has had a low of $0.21 and a high of $1.92. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.00, and a quick ratio of 9.00. The fifty day moving average price for LABP is $0.4107 and a two-hundred day moving average price translates $0.5983 for the stock.
The latest earnings results from Landos Biopharma Inc. (NASDAQ: LABP) was released for Sep, 2022.
Landos Biopharma Inc.(LABP) Company Profile
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company’s lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn’s disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer’s disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
